Physician profile
Thomas Jeneby
NPI 1043264138
$14,837.97
in general payments reported to CMS, 2019-2025
21 companies · $764 in 2025
The $764 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,091 · 2020: $293 · 2021: $1,845 · 2022: $950 · 2023: $1,340 · 2024: $1,554 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,333 · Long Term Medical Supply Or Device Loan: $326.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,332.61 |
| Long Term Medical Supply Or Device Loan | $325.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acelrx Pharmaceuticals, INC. | $4,996.81 | 2019-2021 | |
| Mentor Worldwide LLC | $3,655.06 | 2019-2025 | Mentor Memorygel Resterilizable Gel Sizer, Mentor Cpx 2 Breast Tissue Expander |
| Allergan, INC. | $2,105.37 | 2019 | |
| Merz North America, INC. | $1,402.08 | 2019-2021 | |
| Galderma Laboratories, L.P. | $813.59 | 2021-2025 | |
| Davol INC. | $378.40 | 2022-2024 | Arista Ah Flexitip |
| Integra Lifesciences Corporation | $360.31 | 2023-2025 | Durasorb Monofilament Mesh, Integra, Surgimend |
| Tela Bio, INC. | $345.44 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Heron Therapeutics, INC. | $159.89 | 2023-2024 | Aponvie, Zynrelef |
| Abbvie INC. | $142.68 | 2024 | |
| Tepha INC | $128.36 | 2019 | |
| Smith+Nephew, INC. | $75.34 | 2021-2024 | Lens 4k, Pico |
| Baxter Healthcare | $58.75 | 2020-2022 | |
| Sientra, INC. | $43.66 | 2022 | |
| Abbott Laboratories | $37.86 | 2025 | Proclaim |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $36.86 | 2023 | Trumatch, Xcm Biologic Tissue Matrix |
| Pacira Pharmaceuticals Incorporated | $36.85 | 2019-2024 | Exparel |
| Eisai INC. | $18.05 | 2020 | |
| Organogenesis INC. | $15.11 | 2023 | Puraply |
| Tei Biosciences INC | $14.26 | 2019 | |
| Eagle Pharmaceuticals, INC. | $13.24 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Jeneby listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.